Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan:111:105489.
doi: 10.1016/j.ebiom.2024.105489. Epub 2024 Dec 9.

Post-treatment duration of positivity for standard and ultra-sensitive Plasmodium falciparum antigen-based rapid diagnostic tests, a cohort study from a low-endemic setting in Namibia

Affiliations

Post-treatment duration of positivity for standard and ultra-sensitive Plasmodium falciparum antigen-based rapid diagnostic tests, a cohort study from a low-endemic setting in Namibia

Henry Ntuku et al. EBioMedicine. 2025 Jan.

Abstract

Background: The standard malaria rapid diagnostic test (RDT) and newer ultra-sensitive RDT (uRDT) target Plasmodium falciparum histidine rich protein-2 (HRP2), which persists post-treatment. The duration of test positivity has not previously been studied in a low transmission setting.

Methods: We conducted a longitudinal cohort study in a low transmission setting in Namibia. RDT-positive individuals identified through passive and active case detection were treated and followed weekly for testing by RDT and uRDT, HRP2 quantification, quantitative PCR (qPCR) of parasitemia, and quantitative reverse transcriptase PCR (RT-PCR) of gametocytemia, until RDT and uRDT were negative for two consecutive weeks. Determinants of persistent positivity were identified using Cox proportional hazards models.

Findings: Among 137 participants with complete follow-up and no evidence of resurgence during follow-up, median duration of positivity was 42 days (range: 3-98 range) for RDT, compared to 67 days (range 12-105) for uRDT. In a sub-analysis of those with laboratory data before treatment (n = 60), drug resistance did not explain persistent positivity. Younger age (<15 years versus ≥15 years: aHR: 1.85, 95% CI 1.04-3.30, and 1.67, 95% CI 0.96-2.89, for RDT and uRDT, respectively), higher initial parasite density (highest versus lowest tertile: aHR 0.11, 95% CI 0.04-0.32 and 0.19, 95% CI 0.07-0.48 for RDT and uRDT, respectively), and persistent parasitemia (≥7 days versus reference of <7 days, aHR 0.39, 95% CI 0.20-0.76, and 0.40, 95% CI 0.21-0.76 for RDT and uRDT, respectively) were associated with longer duration of positivity.

Interpretation: Duration of RDT/uRDT positivity was more than double compared to reports from higher endemic settings, potentially due to lower population immunity to clear parasite DNA and antigen. Prolonged duration of positivity compromises their use to detect current infection, but increased detection of recent infection can facilitate surveillance and inform elimination efforts.

Funding: The project was funded by the Bill and Melinda Gates Foundation (A128488 and INV1135840), Horchow Family Fund (5300375400), and Chan Zuckerberg Biohub.

Keywords: Histidine-rich protein; Low transmission; Low-endemic; Malaria; Malaria elimination; Persistence.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests All authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Enrollment and follow-up flowchart.
Fig. 2
Fig. 2
Kaplan–Meier curves of proportion remaining RDT or uRDT positive by days since treatment, n = 137 participants.
Fig. 3
Fig. 3
Boxplots of log10 HRP2 concentration and parasite density by days since treatment, median, interquartile range, minimum and maximum.
Fig. 4
Fig. 4
Kaplan–Meier curves of proportion remaining RDT or uRDT positive by days since treatment, stratified by age category (a), initial parasite density (log10 parasites/μL) (b), and persistence of positivity by qPCR (c), n = 137 participants.

Similar articles

Cited by

References

    1. WHO . 3rd ed. World Health Organization; Geneva, Switzerland: 2015. Guidelines for the treatment of malaria.
    1. UNITAID . 3rd ed. World Health Organization; Geneva, Switzerland: 2016. Malaria diagnostics technology and market landscape.
    1. Gao Y., Zhao Y., Zhang X., Tian J., Guyatt G., Hao Q. Comparing SARS-CoV-2 testing positivity rates and COVID-19 impact among different isolation strategies: a rapid systematic review and a modelling study. EClinicalMedicine. 2023;61 - PMC - PubMed
    1. Dalrymple U., Cameron E., Bhatt S., Weiss D.J., Gupta S., Gething P.W. Quantifying the contribution of Plasmodium falciparum malaria to febrile illness amongst African children. Elife. 2017;6 - PMC - PubMed
    1. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15(1):66–78. - PMC - PubMed

MeSH terms